A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas

Learn more about:
Related Clinical Trial
Recurrence After Whipple’s (RAW): Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Head Malignancy Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care Prospective Evaluation of Biliary Tissue Sampling With ERCP Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture Liver Cancer Registry Platform Target Rare Cancer Knowledge Neoadjuvant Therapy in Biliary Adenocarcinoma BOLD-100 in Combination With FOLFOX for the Treatment of Advanced, Solid Tumours the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Efficacy of Fistulotomy for Biliary Cannulation A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Etomidate vs. Midazolam for Sedation During ERCP Loop-tipped Guidewire in Selective Biliary Cannulation Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm BKM120 in Cancers With PIK3CA Activating Mutations A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT PTFE Stents for Treatment of Malignant Biliary Strictures Irreversible Electroporation of Unresectable Liver Tumors Personal Resilience Empowerment Program Study Radiofrequency Ablation for Biliopancreatic Malignancy Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer In Vitro Models of Liver and Pancreatic Cancer Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Evaluation of Stereotactic Radiosurgery For Liver Malignancies Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD Margin Status After Pancreaticoduodenectomy for Cancer A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer A Study of TRK-950 in Patients With Advanced Solid Tumors Combined HCC-MFCCC Proton Therapy and Bevacizumab for Primary Liver Tumors Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases Fluorescence QRH-882260 Peptide Imaging in the Bile Duct A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer MRCP Diagnoses EHCC Better When Combined DWI Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Comparison of Biliary Forceps Biopsy and Brush Cytology Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Endobiliary RFA for Unresectable Malignant Biliary Strictures A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Clinical Effect and Safety of PDT and RFA for Unresectable EHCC Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma Trial of IRE in Cholangiocarcinoma Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer S-1 in Combination With Abraxane in Treating Cholangiocarcinoma Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol Study of Pembrolizumab and Olaparib in Bile Duct Cancer Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma ncRNAs in Exosomes of Cholangiocarcinoma Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Brief Title

A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas

Official Title

A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas

Brief Summary

      This is a Phase I Dose Escalation Study in which the safety, tolerability and efficacy of
      Amphinex®--induced Photochemical Internalisation (PCI) of Gemcitabine followed by
      Gemcitabine/Cisplatin Chemotherapy will be assessed in patients with advanced inoperable
      cholangiocarcinomas.
    

Detailed Description

      Cholangiocarcinoma (CCA) is an uncommon adenocarcinoma arising from the neoplastic
      transformation of cholangiocytes, the epithelial cells lining the intra-hepatic and
      extra-hepatic bile ducts. CCA accounts for about 3% of all digestive tumours and 10-15% of
      the hepatobiliary tumours. It has an annual incidence of 1-2 cases per 100,000 in the Western
      World, but rates of CCA have been steadily rising worldwide over the past several decades. On
      a global scale, CCA is the second most common primary hepatic malignancy These tumours have a
      poor overall survival with a 5-year survival of about 5%. Over 50% of patients present with
      advanced-stage disease, and the prognosis is poor with the survival of between 6-12 months
      for unresected patients, even after biliary decompression. CCA may arise anywhere in the
      biliary tree, from the small, peripheral hepatic ducts to the distal common bile duct.
      Commonly used classification systems utilise anatomical location to group tumours into three
      main categories: intra-hepatic (20-25%), perihilar (also including hilar/Klatskin tumour -
      50%) and distal (20-25%).

      Hilar CCA is an adenocarcinoma of the extrahepatic biliary tree arising from the main left or
      right hepatic ducts or their confluence. There has a been a growing recognition that hilar
      CCA disease actually has a distinct biological behaviour and natural history compared to that
      of (distal) extra-hepatic CCA, and increasing acknowledgment that different therapeutic
      strategies are required. At initial presentation of patients with extra-hepatic CCA, 30-50%
      will have local lymph node involvement and 10-20% metastatic spread typically to the liver
      and peritoneum. With hilar CCA due to the long asymptomatic course, only 20% are resectable
      at time of diagnosis.

      Standard treatment options for CCA include surgery, radiotherapy and chemotherapy, dependent
      upon if the CCA is intra- or extra-hepatic. Tumour resection is the only potential cure for
      CCA. Recent advances in transplantation using stringent selection criteria and utilization of
      neoadjuvant chemoradiation have demonstrated encouraging results with 5 year survival rates
      of over 70%, with even one series from The Mayo Clinic yielding a 5-year survival rate of
      82%. For the 80% who present with unresectable disease, the utility of these modalities
      combined with biliary decompression interventions only provided a median survival time of 3-6
      months from the time of diagnosis.

      For these patients with inoperable advanced CCA the main treatment aim is palliative to
      relieve local symptoms such as pain and jaundice. Surgery for these patients is primarily for
      creating a bypass in patients who cannot be stented. CCA is remarkably resistant to
      pharmacological therapy, but activity has been seen using chemotherapy; mainly gemcitabine
      given either as monotherapy or paired with either a platin derivative or a fluoropyrimidine
      as a doublet treatment and more recently docetaxel, these give partial response (PR) rates of
      0-9% and an average survival advantage of 2-12 months. Concerning biological therapy, the
      ongoing studies using sorafenib, lapatinib or bevacizumab have yielded some promising
      results, with sorafenib demonstrating therapeutic benefit in a single arm Phase II study. For
      patients who are unsuitable for curative resection, the current systemic combination
      chemotherapy is with cisplatin plus gemcitabine. This was established in the largest
      randomized phase III study to date in non-operable biliary tract cancer which demonstrated a
      response rate of 81.4% and a median overall survival (OS) of 11.7 months; notably there was
      no statistically significant increase in toxicity when compared to gemcitabine monotherapy.
      The recent advances in interventional and endoscopic technology have seen a rise in highly
      specialized centres that are able to deliver very precise local control treatments aimed at
      gaining local control; these include local ablation and embolization, brachytherapy,
      radio-frequency ablation and, most significantly, photodynamic therapy which (PDT), with its
      favourable adverse-event profile, is recommended by most recent review articles for
      non-resectable patients.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Dose-limiting toxicities (DLT) and the safety profile

Secondary Outcome

 Measuring the Amphinex and Gemcitabine concentration in blood plasma

Condition

Cholangiocarcinoma

Intervention

Amphinex, Gemcitabine and Cisplatin

Study Arms / Comparison Groups

 Phase I
Description:  Experimental PCI treatment in dose escalation cohorts consist of Amphinex injection (at different doses) plus a single standard dose of Gemcitabine (1000 mg/m2) plus intraluminal light at the tumour area (at different doses). In addition up to 8 cycles of standard chemotherapy doses of Gemcitabine (1000 mg/m2) and Cisplatin (25 mg/m2) was provided. In the Extended part of the study (last cohort) an additional PCI treatment was introduced at Cycle 5 in the treatment Schedule.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

24

Start Date

May 2013

Completion Date

February 2019

Primary Completion Date

February 2019

Eligibility Criteria

        Inclusion Criteria:

          1. Histopathologically/cytologically (C5) verified adenocarcinoma consistent with
             cholangiocarcinoma

          2. Cholangiocarcinoma that:

               -  Is considered to be inoperable

               -  Has a primary lesion in the perihilar biliary duct region that requires stent
                  placement

               -  Has nodal enlargement ≤ to N1 as per CT/MRI assessment

               -  If has metastatic disease; this should be confined to the liver parenchyma only

          3. Adequate biliary drainage (either at least 50% of the liver volume, or at least two
             sectors), with no evidence of active uncontrolled infection (patients on antibiotics
             are eligible).

          4. Age ≥ 18 years.

          5. Performance status ECOG ≤ 1.

          6. Estimated life expectancy of at least 12 weeks.

          7. Written informed consent.

        Exclusion Criteria:

          1. Any prior anti-cancer (either local or systemic) treatment for cholangiocarcinoma.

          2. Patients with extra-hepatic metastatic cholangiocarcinoma.

          3. Patients with a severe visceral disease other than cholangiocarcinoma.

          4. Patients with primary sclerosing cholangitis.

          5. Patients with porphyria or hypersensibility to porphyrins.

          6. Patients with an active second primary cancer, with exception of adequately treated
             basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer,
             or in-situ carcinoma of the uterine cervix. An active second primary cancer is defined
             as one with a disease-free interval of < 5 years before registration/randomization.

          7. Inability to undergo CT or MRI.

          8. Current participation in any other interventional clinical trial.

          9. Male patients not willing to use adequate contraception or female patients of
             childbearing potential not willing to use an effective form of contraception such as
             hormonal birth control, intrauterine device or double barrier method during PCI
             treatment and subsequent chemotherapy and for at least 6 months thereafter.

         10. Breast feeding women or women with a positive pregnancy test at baseline.

         11. Inadequate bone marrow function:

             Absolute Neutrophil Count (ANC): < 1.5 x 10^9/L, or platelet count < 100 x 10^9/L or
             haemoglobin < 6 mmol/L (transfusion allowed).

         12. Inadequate liver function, defined as:

               -  Serum (total) bilirubin > 2.5 x the Upper Limit of Normal (ULN) for the
                  institution.

               -  Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) > 3.0 x ULN
                  (> 5 x ULN if liver metastases are present)

               -  Alkaline phosphatase (ALP) levels > 5.0 x ULN.

         13. Inadequate renal function, defined as:

             Creatinine clearance < 60 mL/min

         14. Planned surgery, endoscopic examination or dental treatment in the first 30 days after
             PCI treatment.

         15. Co-existing ophthalmic disease likely to require slit-lamp examination within the
             first 90 days after PCI treatment.

         16. Clinically significant and uncontrolled cardiac disease including unstable angina,
             acute myocardial infarction within six months prior to baseline, congestive heart
             failure, and arrhythmia requiring therapy, with the exception of extra systoles or
             minor conduction abnormalities and controlled and well treated chronic atrial
             fibrillation.

         17. Known allergy or sensitivity to photosensitisers.

         18. Ataxia telangiectasia.

         19. Evidence of any other medical conditions (such as psychiatric illness, infectious
             diseases, physical examination or laboratory findings) that may interfere with the
             planned PCI treatment, affect patient compliance or place the patient at high risk
             from treatment-related complications.

         20. Significant hearing impairment.

         21. Patients concurrently receiving phenytoin.

         22. Patients defined as vulnerable according to French law (France only)

         23. Patients using or have been using photosensitising drugs within the last 7 days
             (France only)

         24. Patients who have received amiodarone in the last year (France only)
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Dr Richard Sturgess, MD, , 

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT01900158

Organization ID

PCI A202/12

Secondary IDs

2012-002888-10

Responsible Party

Sponsor

Study Sponsor

PCI Biotech AS


Study Sponsor

Dr Richard Sturgess, MD, Principal Investigator, University Hospital Aintree


Verification Date

August 2019